Pure Global
NCT05536752

QA102 Phase II Study in Subjects With Dry AMD

A Phase 2, Double-Masked, Randomized, Placebo-Controlled, Dose-Response Study Assessing the Safety and Efficacy of QA102 in Subjects With Dry Age-Related Macular Degeneration (AMD)
Smilebiotek Zhuhai Limited·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Dry Age-related Macular Degeneration
Drug/Device/Intervention
QA102/Placebo
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Smilebiotek Zhuhai Limited
Location
Plano, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Sep 22, 2022
End date
Oct 01, 2025
Enrollment
240 participants
Primary outcome

proportion of subjects with disease progression to CNV or significant GA change as defined in the protocol

Summary

This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The
 primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the
 development of GA or CNV in high-risk eyes.

ICD-10 classifications
Peripheral retinal degenerationCorneal degenerationHereditary retinal dystrophyOptic atrophy in diseases classified elsewhereDisorders of choroid and retina
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05536752
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05536752 through Pure Global AI's free database. This Phase 2 trial is sponsored by Smilebiotek Zhuhai Limited and is currently Recruiting. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 240 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.